US5324571083 - Common Stock
ELI LILLY & CO
NYSE:LLY (11/21/2024, 12:16:10 PM)
744.31
-9.1 (-1.21%)
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 43,000 full-time employees. The firm discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The firm manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.
ELI LILLY & CO
Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr
Indianapolis INDIANA 46285
P: 13172762000
CEO: David A. Ricks
Employees: 43000
Website: https://www.lilly.com/
Shares of Lilly are cratering, but investors may be surprised to learn what's influencing the volatility.
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Novo Nordisk and its rival Eli Lilly are visiting HR teams and labor unions across the country to make the case for anti-obesity drugs
Here you can normally see the latest stock twits on LLY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: